Literature DB >> 23582913

Epidemiology of gastroenteropancreatic neuroendocrine tumours.

M Fraenkel1, M K Kim, A Faggiano, G D Valk.   

Abstract

Gastroenteropancreatic neuroendocrine tumours are a heterogeneous group of tumours arising from diffuse endocrine cells, causing unique clinical syndromes. These tumours, formerly named carcinoid, can involve any part of the gastrointestinal tract and the endocrine pancreas and have a wide range of malignant potential: from benign to poorly differentiated tumours. In this review we will summarize the data available on the epidemiology of gastroenteropancreatic tumours as it is reported from around the world. This includes annual incidence rates at the various anatomic sites, and trends in incidence rates with time. In addition age and stage at presentation, gender and racial differences and finally prognosis and survival were collected when reported.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23582913     DOI: 10.1016/j.bpg.2013.01.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  63 in total

Review 1.  Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2016-09-23       Impact factor: 3.889

2.  Important of case-reports/series, in rare diseases: Using neuroendocrine tumors as an example.

Authors:  Taichi Nakamura; Hisato Igarashi; Tetsuhide Ito; Robert T Jensen
Journal:  World J Clin Cases       Date:  2014-11-16       Impact factor: 1.337

3.  Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).

Authors:  Sylvain Manfredi; Thomas Walter; Eric Baudin; Romain Coriat; Philippe Ruszniewski; Thierry Lecomte; Anne-Pascale Laurenty; Bernard Goichot; Vincent Rohmer; Guillaume Roquin; Oana-Zvetlana Cojocarasu; Catherine Lombard-Bohas; Côme Lepage; Jeff Morcet; Guillaume Cadiot
Journal:  Endocrine       Date:  2017-06-29       Impact factor: 3.633

Review 4.  Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.

Authors:  Sara Pusceddu; Elena Verzoni; Natialie Prinzi; Alessia Mennitto; Daniela Femia; Paolo Grassi; Laura Concas; Claudio Vernieri; Giuseppe Lo Russo; Giuseppe Procopio
Journal:  Ther Adv Med Oncol       Date:  2017-01-11       Impact factor: 8.168

Review 5.  Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors.

Authors:  Keunyoung Kim; Seong-Jang Kim
Journal:  Nucl Med Mol Imaging       Date:  2017-11-20

Review 6.  Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; James R Howe
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

7.  Metastatic neuroendocrine tumor of the esophagus with features of medullary thyroid carcinoma.

Authors:  Raymond M Fertig; Adam Alperstein; Carlos Diaz; Kyle D Klingbeil; Sameera S Vangara; Ryosuke Misawa; Jennifer Reed; Sudeep Gaudi
Journal:  Intractable Rare Dis Res       Date:  2017-08

Review 8.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

9.  Lymph Node Metastasis in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jacob A Martin; Richard R P Warner; Anne Aronson; Juan P Wisnivesky; Michelle Kang Kim
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

10.  Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome.

Authors:  Andrew Hanna; Caroline Kim-Kiselak; Rebecca Tang; David C Metz; Zhaohai Yang; Ronald DeMatteo; Douglas L Fraker; Robert E Roses
Journal:  Ann Surg Oncol       Date:  2021-06-13       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.